|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:administered_by
|
subcutaneous injection
|
|
gptkbp:approves
|
gptkb:1998
gptkb:FDA
|
|
gptkbp:available_on
|
auto-injector
pre-filled syringe
|
|
gptkbp:biologic_class
|
gptkb:fusion
|
|
gptkbp:brand
|
gptkb:Enbrel
Etanercept
|
|
gptkbp:chemical_formula
|
C6 H7 N3 O2 S
|
|
gptkbp:class
|
tumor necrosis factor inhibitor
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:clinical_use
|
gptkb:juvenile_idiopathic_arthritis
autoimmune diseases
chronic inflammatory diseases
dermatological conditions
|
|
gptkbp:contraindication
|
active infections
severe heart failure
hypersensitivity to etanercept
|
|
gptkbp:discovered_by
|
gptkb:Immunex_Corporation
|
|
gptkbp:dosage_form
|
gptkb:Software_Solutions
|
|
gptkbp:duration
|
long-term
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
etanercept
|
|
gptkbp:interacts_with
|
gptkb:methotrexate
other immunosuppressants
|
|
gptkbp:invention
|
2028
|
|
gptkbp:is_monitored_by
|
liver function tests
complete blood count
tuberculosis screening
|
|
gptkbp:lifespan
|
3 to 6 days
|
|
gptkbp:manufacturer
|
gptkb:Amgen
|
|
gptkbp:marketed_as
|
gptkb:Enbrel
|
|
gptkbp:mechanism_of_action
|
inhibits TNF-alpha
|
|
gptkbp:patient_population
|
gptkb:children
adults
|
|
gptkbp:pharmacokinetics
|
subcutaneous absorption
distribution volume
excretion in urine
metabolism by proteolysis
|
|
gptkbp:rounds
|
renal
|
|
gptkbp:route_of_administration
|
subcutaneous
|
|
gptkbp:side_effect
|
headache
nausea
abdominal pain
injection site reactions
autoimmune disorders
malignancy risk
increased risk of infection
demyelinating disorders
heart failure exacerbation
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:used_for
|
gptkb:juvenile_idiopathic_arthritis
gptkb:rheumatoid_arthritis
gptkb:ankylosing_spondylitis
psoriasis
|
|
gptkbp:weight
|
150 k Da
|
|
gptkbp:bfsParent
|
gptkb:Enbrel
|
|
gptkbp:bfsLayer
|
5
|